Crosslinking of corneal collagen with riboflavin and ultraviolet-A irradiation (CXL) induces crosslinks within and between collagen fibres. CXL increases corneal biomechanical and biochemical stability,
1
and is currently used clinically to treat keratectasia.
2 3 CXL also significantly reduces the stromal swelling capacity. 4 We investigated whether a modified CXL treatment protocol would be beneficial in early Fuchs dystrophy with various degrees of corneal oedema and diurnal variations in visual acuity.
MATERIALS AND METHODS
CXL was performed as published previously, 2 with the following modification: in cases where the stroma was thicker than 450 mm after abrasion and 30 min of instillation of isoosmolar riboflavin solution, glycerol 70% solution was applied every 5 s for 2 min, and the central corneal thickness (CCT) was measured using ultrasound pachymetry (Tomey GmbH, Erlangen, Germany). Glycerol 70% solution was administered repeatedly until the target corneal thickness of 370e430 mm was reached. During irradiation (UV-X, Peschke Meditrade, Cham, Switzerland), CCT was monitored by ultrasound pachymetry every 5 min, and glycerol 70% solution was applied, if necessary.
RESULTS
Three eyes in two patients were treated using this modified CXL protocol. A 50-yearold woman with Fuchs dystrophy and a history of 3 years of diurnal visual fluctuations was referred to us in March 2008. The preoperative best spectacle-corrected visual acuity (BSCVA) was 20/50. We performed modified CXL in the left eye.
At 1 month after CXL, Scheimpflug analysis (Pentacam, Oculus Instruments, Wetzlar, Germany) of CCT showed a reduction of more than 100 mm, and the corneal thickness spatial profile (CTSP) and percentage of increase in thickness (PIT) showed a regularisation of the 'flattening' typical for Fuchs dystrophy (figure 1). Accordingly, diurnal analysis of corneal thickness showed a distinct postoperative reduction in CCT at all time points measured (figure 2). One month after CXL, the patient reported a reduction in diurnal visual fluctuations, and we measured an increase in BSCVA to 20/32. The patient showed stable topographical and visual acuity at the 3-month follow-up.
DISCUSSION
Fuchs endothelial dystrophy is characterised by corneal swelling and oedema. In early stages of the disease, the endothelial proton pump is compromised, leading to diurnal CCT variations and fluctuations in visual acuity. Since CXL reduces the corneal swelling capacity, 4 we investigated whether CXL would be beneficial in early Fuchs dystrophy.
We modified the standard CXL treatment protocol by reducing corneal thickness prior to irradiation. Because the standard parameters only treat the anterior 270e330 mm, 1 we used glycerol 70% solution intraoperatively to dehydrate and thin the cornea prior to and during irradiation.
We saw a distinct reduction in CCT, an improvement in the corneal thickness spatial profile (CTSP) and an increase in BSCVA 1 month after treatment which remained stable at the 3-month follow-up. 
